Cancer clinical trials in the region Bourgogne-Franche-Comté
223 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT06492616
#2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
20 recruiting sites
Stemline Therapeutics, Inc.
Phase 3
Colon cancer
Rectal cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3
Sarcoma and GIST
#NCT04307277
#2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1
Grade 2
Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3
Breast cancer
#NCT06982521
#2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
1
2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
Hormone therapy
Excluded genetic anomalies
AKT
PTEN
Excluded previous treatments at localized stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
17 recruiting sites
Relay Therapeutics, Inc.
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06476184
#2023-508260-30-01
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
36 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3
Lung cancer
#NCT06937905
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07544654
#2025-523869-22-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
4 recruiting sites
Boehringer Ingelheim
Phase 3
Lung cancer
#NCT06899126
#2024-515658-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Antibody Drug Conjugates (ADC)
17 recruiting sites
Daiichi Sankyo